FDA Should Ease Criteria For Some Renal Studies, Advisory Cmte. Says
FDA should amend its new renal testing guidance to reflect real-world conditions and ease the burden - in at least one area - for sponsors, according to an FDA advisory committee. With an eye toward facilitating clinical testing, the panel recommended that the agency change its patient selection criteria for one segment of pharmacokinetics studies on the effect of renal impairment on drug dosing
You may also be interested in...
US FDA advisory committee finds merit in each of four industry-suggested alternative approaches to the current paradigm for assessing the impact of renal impairment on drug exposures; agency's own 2010 draft guidance does not reflect its current thinking on the design of dedicated pharmacokinetic studies.
Subjects with psychiatric conditions are often excluded from trials, an agency study finds, which “doesn’t seem a good thing” to Bob Temple.
FDA is exploring a pharmacological approach for identifying a drug's safety characteristics so sponsors can assess risk earlier in the drug development process